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Abstract 
Management bundles that define items or procedures strongly recommended in clinical practice 
have been used in many guidelines in recent years. Application of these bundles facilitates the 
adaptation of guidelines and helps improve the prognosis of target diseases. In Tokyo Guidelines 
2013 (TG13), we proposed management bundles for acute cholangitis and cholecystitis. Here, in 
Tokyo Guidelines 2018 (TG18), we redefine the management bundles for acute cholangitis and 
cholecystitis. Critical parts of the bundles in TG18 include the diagnostic process, severity 
assessment, transfer of patients if necessary, and therapeutic approach at each time point. Observance 
of these items and procedures should improve the prognosis of acute cholangitis and cholecystitis. 
Studies are now needed to evaluate the dissemination of these TG18 bundles and their effectiveness.  
 
Introduction 
Detailed guidelines are now being released in many fields of medicine, and it is not easy for 
clinical physicians to keep all of the contents of these guidelines in mind when treating patients. 
Nevertheless, to improve patient prognosis, such guidelines need to be widely disseminated and used 
in clinical practice. Using bundles in health care simplifies complex patient care processes. A bundle 
is a selected set of elements of care that are distilled from evidence-based practice guidelines and that, 
when implemented as a group, have an effect on outcomes beyond that achieved when the individual 
elements are implemented alone.  
We proposed management bundles for acute cholangitis and cholecystitis in Tokyo Guidelines 
2013 (TG13) [1]. Here, as part of TG18, we propose a new flowchart for the treatment of acute 
cholecystitis and have made several changes to the clinical practice guidelines for managing acute 
cholangitis and acute cholecystitis.  
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Efficacy of the bundles 
A good example for the effectiveness of using bundles is the sepsis bundles in the Surviving 
Sepsis Campaign Guidelines. Sepsis bundles were introduced in 2008, and improvements in 
compliance and survival with the bundles were investigated in a number of studies [2]- [6]. These 
reports showed a marked reduction in hospital mortality rates in patients whose care included 
compliance with most of the bundles.  
To encourage adherence to clinical guidelines and improve care processes, the Institute for 
Healthcare Improvement developed the concept of “care bundles” [7] in critical care patients. Various 
strategies such as education (86%), reminders (71%), and audit and feedback (63%) have been used to 
encourage the implementation of the care bundles in intensive care units ([8], 26276569). 
As with TG13, in the process of developing TG18, mandatory items or procedures to be included 
in the management bundles have been discussed and defined among Tokyo Guidelines Revision 
Committee members. On the basis of the recommendations in TG18, those items that are expected to 
yield favorable treatment results have been included in the bundles to assure the appropriate 
interventions for acute cholangitis and cholecystitis at the appropriate times. The TG13 checklists also 
have been updated to confirm compliance with the bundles. 
 
Acute cholangitis management bundle (Table 1) 
Few changes have been made in the TG18 management bundle for acute cholangitis compared 
with the TG13 one, with the exception of the addition of recommendations for patient transfer [9]. If 
acute cholangitis is suspected, perform a diagnostic assessment by using the TG18 diagnostic criteria 
[10]. If a definitive diagnosis cannot be made, reassess the patient every 6 to 12 h using the diagnostic 
criteria. Use the severity assessment criteria [9] to assess severity repeatedly: at diagnosis, within 24 h 
after diagnosis, and again during the next 24 to 48 h. Provide initial treatment, such as sufficient fluid 
replacement, electrolyte compensation, and intravenous administration of analgesics and full-dose 
antimicrobial agents, as soon as a diagnosis has been made [11]. Perform biliary drainage, and culture 
the blood or bile, or both, if the condition is sufficiently severe [12]. If the hospital is not equipped to 
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perform endoscopic or percutaneous transhepatic biliary drainage or to provide intensive care, transfer 
patients with moderate or severe cholangitis to a hospital that is capable of providing these treatments. 
 
Acute cholecystitis management bundle (Table 2) 
If acute cholecystitis is suspected, diagnostic assessment is made by using the TG18 diagnostic 
criteria [13]. If a definite diagnosis cannot be made, reassess the patient every 6 to 12 h using the 
diagnostic criteria. Use the severity assessment criteria [13] to assess the severity repeatedly: at 
diagnosis, within 24 h after diagnosis, and again at 24 to 48 h, and evaluate the surgical risk (e.g. 
presence of local inflammation, Charlson comorbidity index, American Society of Anesthesiologists 
physical status classification, or the predictive factors). Taking into consideration the need for 
cholecystectomy, as soon as a diagnosis has been made, initiate treatment, including sufficient fluid 
replacement, electrolyte compensation, fasting, and administration of intravenous analgesics and 
full-dose antimicrobial agents [11,13]. Urgent or early laparoscopic cholecystectomy (Lap-C), urgent 
or early biliary drainage, and blood or bile culture (or both) should be performed according to the 
severity and surgical risk [14-17]. Consider transferring the patient to advanced facilities if facilities 
for urgent or emergency Lap-C, biliary drainage, and intensive care are not available [14]. 
 
Checklist for the use of management bundles for acute cholangitis and cholecystitis (Tables 3, 4) 
Checklists are given to ensure effective use of the bundles. Use of these lists in medical care 
ensures that standards are maintained and is thought to improve the effectiveness of the bundles. The 
TG13 checklists also have been updated to confirm compliance with the bundles [1]. A checklist of 
the procedures, laboratory tests, monitoring, and interventions required should be placed at the 
patient’s bedside. 
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Conclusions 
Bundles consist of important items and procedures for the effective application of TG18. Reports 
from various facilities have demonstrated that improved prognosis can be expected through the use of 
the Tokyo Guidelines for acute cholangitis and cholecystitis. 
Future evaluations of the distribution of TG18 bundles and of changes in prognosis will provide 
evidence for the future construction and revision of TG18. 
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Table 1 Management bundle for acute cholangitis 
1. When acute cholangitis is suspected, perform a diagnostic assessment every 6 to 12 h using TG18 
diagnostic criteria until a diagnosis is reached ..  
2. Perform abdominal US, followed by a CT scan, MRI, MRCP, and HIDA scan as required. 
3. Use the severity assessment criteria to assess severity repeatedly: at diagnosis, within 24 h after 
diagnosis, and from 24 to 48 h after diagnosis. 
4. As soon as a diagnosis has been made, provide initial treatment. The treatment is as follows: 
sufficient fluid replacement, electrolyte compensation, and intravenous administration of 
analgesics and full-dose antimicrobial agents. 
5. In patients with Grade I (mild) disease, if no response to the initial treatment is observed within 24 
h, perform biliary tract drainage immediately. 
6. In patients with Grade II (moderate) disease, perform biliary tract drainage immediately along with 
the initial treatment. If early drainage cannot be performed because of a lack of facilities or skilled 
personnel, consider transferring the patient. 
7. In patients with Grade III (severe) disease, perform urgent biliary tract drainage along with the 
initial treatment and give general supportive care. If urgent drainage cannot be performed because 
of a lack of facilities or skilled personnel, consider transferring the patient. 
8. In patients with Grade III (severe) disease, supply organ support (e.g. noninvasive/invasive positive 
pressure ventilation, use of vasopressors and antimicrobial agents) immediately. 
9. Perform blood culture or bile culture, or both, in Grade II (moderate) and III (severe) patients. 
10. Consider treating the etiology of acute cholangitis with endoscopic, percutaneous, or operative 
intervention once the acute illness has resolved. Cholecystectomy should be performed for 
cholecystolithiasis after the acute cholangitis has resolved. 
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11. If the hospital is not equipped to perform endoscopic or percutaneous transhepatic biliary drainage 
or provide intensive care, transfer patient with moderate or severe cholangitis to a hospital capable 
of providing these treatments. 
US, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; MRCP, 
magnetic resonance cholangiopancreatography; HIDA, hepatobiliary iminodiacetic acid 
 
Table 2 Management bundle for acute cholecystitis 
1. When acute cholecystitis is suspected, perform a diagnostic assessment every 6 to 12 h using TG18 
diagnostic criteria until a diagnosis is reached . 
2. Perform abdominal US, followed by a CT scan or HIDA scan if needed to make a diagnosis. 
3. Use the severity assessment criteria to assess severity repeatedly: at diagnosis, within 24 h after 
diagnosis, and from 24 to 48 h after diagnosis. Evaluate the surgical risk (e.g. local inflammation, 
CCI, ASA, PS, predictive factors). 
4. Taking into consideration the need for cholecystectomy, as soon as a diagnosis has been made, 
initiate treatment, with sufficient fluid replacement, electrolyte compensation, fasting, and 
administration of intravenous analgesics and full-dose antimicrobial agents. 
5. In Grade I (mild) patients, laparoscopic cholecystectomy (Lap-C) at an early stage, i.e. within 7 
days (within 72 h is better) of onset of symptoms is recommended. 
6. If conservative treatment is selected for patients with Grade I (mild) disease and no response to 
initial treatment is observed within 24 h, reconsider early Lap-C if patient performance status is 
good and fewer than 7 days have passed since symptom onset or biliary tract drainage. 
7. In Grade II (moderate) patients, consider urgent/early Lap-C if patient performance status is good 
and the advanced Lap-C technique is available. If the patient’s condition is poor, urgent/early 
biliary drainage, or delayed/elective Lap-C, can be selected. 
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8. In Grade III (severe) patients with high surgical risk*, perform urgent/early biliary drainage. If 
there are neither negative predictive factors** nor FOSF*** and the patient has good PS, early 
Lap-C at an advanced center can be chosen. 
9. Perform blood culture or bile culture, or both, in Grade II (moderate) and III (severe) patients. 
10. Consider transferring the patient to advanced facilities if urgent/emergency Lap-C, biliary 
drainage, and intensive care are not available. 
US, ultrasonography; CT, computed tomography; HIDA, hepatobiliary iminodiacetic acid; CCI; 
Charlson Comorbidity Index; ASA, American Society of Anesthesiologists class; PS, performance 
status 
*high surgical risk: evaluate CCI, ASA, PS, predictive factors, and FOSF 
**predictive factors: jaundice (T-Bil ≥2), neurological dysfunction, respiratory dysfunction 
***FOSF: favorable organ system failure = cardiovascular or renal organ system failure that is rapidly 
reversible after admission and before early Lap-C in acute cholecystitis 
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Table 3 Acute cholangitis bundle checklist 
 
□ Repeat the diagnosis every 6 to 12 h 
□ Perform diagnostic imaging: abdominal US followed by CT scan, MRI, MRCP, and HIDA scan as 
needed. 
□ Assess severity at diagnosis, within 24 h; and from 24 to 48 h after diagnosis.. 
□ After diagnosis, immediately start antibiotic administration and general supportive care. 
□ Grade I (mild): perform biliary drainage when no symptom improvement is observed within 24 h. 
□ Grade II (moderate): perform biliary drainage immediately. 
□ Grade III (severe): apply organ support and emergency biliary drainage. 
□ Consider transfer when the above procedures are unavailable. 
□ Grade II (moderate) and III (severe): culture blood or bile or both. 
□ Consider surgical procedures to remove causes after biliary drainage and amelioration of organ 
failure. 
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Table 4 Acute cholecystitis bundle checklist 
 
□ Repeat the diagnosis every 6 to 12 h. 
□ Perform diagnostic imaging: US, followed by CT and HIDA scan 
□ Assess severity at diagnosis and within 24 h after diagnosis; repeat severity assessment every 24 h 
and evaluate surgical risk. 
□ Immediately initiate antibiotic administration and general supportive care. 
□ Grade I (mild): perform laparoscopic cholecystectomy (Lap-C) at an early stage within 7 days 
(within 72 h is better) of onset of symptoms. 
□ Conservative treatment for Grade I (mild): if condition is worsening or no improvement is observed 
within 24 h, reconsider early Lap-C if fewer than 7 days since biliary drainage (cholecystostomy).  
□ Grade II (moderate): perform urgent/early Lap-C if patient performance status is good and 
advanced Lap-C technique is available. If not, urgent/early biliary drainage or delayed/elective 
Lap-C can be selected. 
□ Grade III (severe): perform urgent/early biliary drainage in patients with high surgical risk. If there 
are neither negative predictive factors nor FOSF and the patient has a good PS, early Lap-C at an 
advanced center can be chosen. 
□ Grade II (moderate) and III (severe): culture blood or bile or both. 
□ Consider transferring the patient to advanced facilities if urgent/emergency Lap-C, biliary drainage, 
and intensive care are not available. 
 
 
